Role of metformin in COVID-19 patients with diabetes.
Not Applicable
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2022/02/040064
- Lead Sponsor
- Manipal Academy Of Higher Education
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients on metformin, patients who are hospitalized with covid-19.
Exclusion Criteria
Patients with other chronic conditions
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MortalityTimepoint: January 2022, December 2022
- Secondary Outcome Measures
Name Time Method umber of readmission <br/ ><br>In hospital mortality <br/ ><br>number of days hospitalised <br/ ><br>number of days on ventilation <br/ ><br>change in level of inflammatory markers <br/ ><br>Clinical improvementTimepoint: January 2022, December 2022
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain metformin's potential antiviral effects in SARS-CoV-2 infected diabetic patients?
How does metformin compare to other biguanides in modulating immune response in diabetic COVID-19 patients?
What biomarkers correlate with improved clinical outcomes in diabetic patients receiving metformin during SARS-CoV-2 infection?
What are the potential adverse events associated with metformin use in diabetic patients with severe SARS-CoV-2 pneumonia?
How does metformin combination therapy with GLP-1 receptor agonists affect clinical outcomes in diabetic SARS-CoV-2 patients?